JSK Therapeutics
JSK Therapeutics is dedicated to developing innovative nitric oxide (NO) donor therapeutics for cancer treatment, aiming to bring first-in-class, safe, and effective solutions to improve patients' lives. Their mission is to aggressively develop treatments for multiple types of cancer and position themselves as a leader in NO therapeutics, with a focus on reducing side effects and enhancing safety profiles.
Industries
Nr. of Employees
small (1-50)
Products
NO donor small-molecule therapeutic candidate (oncology)
A small-molecule nitric oxide donor candidate being developed for multiple cancer indications with an emphasis on favorable safety profile and potential co-therapeutic use.
Veterinary indication development program
Development program adapting NO-donor chemistry for animal health applications and veterinary formulations.
Antiviral indication development program
Exploratory program investigating antiviral applications of NO-donor small-molecule chemistry.
NO donor small-molecule therapeutic candidate (oncology)
A small-molecule nitric oxide donor candidate being developed for multiple cancer indications with an emphasis on favorable safety profile and potential co-therapeutic use.
Veterinary indication development program
Development program adapting NO-donor chemistry for animal health applications and veterinary formulations.
Antiviral indication development program
Exploratory program investigating antiviral applications of NO-donor small-molecule chemistry.
Services
Drug development program management
Project management and execution of preclinical development activities to advance small-molecule candidates through translational milestones.
Regulatory and orphan designation planning
Strategic planning to pursue orphan drug pathways and related regulatory strategies for specialized indications.
Drug development program management
Project management and execution of preclinical development activities to advance small-molecule candidates through translational milestones.
Regulatory and orphan designation planning
Strategic planning to pursue orphan drug pathways and related regulatory strategies for specialized indications.
Expertise Areas
- Oncology drug development
- Nitric oxide (NO) donor therapeutics
- Medicinal chemistry and small-molecule design
- Preclinical development and safety evaluation
Key Technologies
- Nitric oxide donor chemistry
- Small-molecule synthesis and optimization
- Preclinical pharmacology and in vivo models
- Toxicology and safety assessment